FDA Orange Book · active-ingredient family
Belinostat
Belinostat is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:BELEODAQ · NDA 206256
1
Brand (NDA)
0
Generics (ANDA)
2
Listed patents
0
Exclusivity periods
Brand (NDA) products · powder
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| BELEODAQRLD | ACROTECH BIOPHARMA | NDA 206256 | — | Jul 03, 2014 |
Listed patents (2)
| Patent | Expires | In | Type |
|---|---|---|---|
| 6888027 | Aug 10, 2026 | in 2 mo | SubstanceProductU-1544 |
| 8835501 | Oct 27, 2027 | in 1 yr 5 mo | Product |
Belinostat — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
